Latest Share Purchase Plans News

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Sparc Technologies has made its inaugural commercial delivery of ecosparc®, a graphene additive, to a major coatings manufacturer, underpinning its push to dominate the protective coatings market. The company also launched a discounted Share Purchase Plan to fuel ongoing commercial expansion.

Podium Minerals' recent share purchase plan secured $1.56 million, significantly below its $4 million underwritten target, leaving a $2.44 million shortfall to be addressed.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

NOVONIX Limited posted a $24.6 million half-year loss while delivering a critical synthetic graphite sample to Panasonic and reaffirming a 2027 production start. The company raised $21.7 million to fund its North American battery materials expansion amid ongoing U.S. trade and policy developments.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Cadence Opportunities Fund (ASX: CDO) is offering eligible shareholders a chance to buy up to $30,000 of shares at a 3.5% discount to market price, following a 30.3% portfolio gain for FY26 and a 41% total shareholder return.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.

Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Staude Capital Global Value Fund Limited posted a 47% drop in net profit after tax for FY2026 amid a 39% revenue decline, while adjusted pre-tax NTA rose 7%. The company declared a fully franked final dividend of 3.3 cents per share and completed a $18.2 million share purchase plan last year.

Argo Global Listed Infrastructure Limited has renewed its on-market buy-back facility for another year, allowing up to 9.4 million shares to be repurchased as part of ongoing capital management.